Navigation Links
Grand Challenges in Global Health initiative funds Yale project

Yale has been offered $17 million from the Grand Challenges in Global health initiative to genetically engineer mice with immune systems similar enough to humans to aid in testing the safety and effectiveness of potential vaccines.

Funded by the Bill & Melinda Gates Foundation, the Yale project will be headed by Richard A. Flavell, M.D., Sterling Professor and Chair of Immunobiology at Yale University School of Medicine, and Howard Hughes Medical Institute investigator.

Flavell and his team will study a novel solution to a problem facing many vaccine developers. Some of the most promising vaccines for HIV and a range of other diseases are made from weakened versions of the infectious agent. These cannot be studied in human trials unless researchers are confident that they are safe.

"A big need in the world of vaccine development is the ability to predict whether vaccines for humans are safe and effective," said Flavell. "We are grateful to the Grand Challenges in Global Health Initiative for providing the funds to develop a predictive model system for vaccine testing."

Yale School of Medicine Dean Robert Alpern, M.D., said, "This generous grant from the Grand Challenges in Global Health Initiative provides a boost to Yale's ongoing initiatives in basic science and clinical research. It will advance research on diseases that have an effect on communities worldwide."

The goal of this award is to provide to the research community a suitable model system to test live attenuated vaccines for use in the developing world. Flavell said the mice generated would be made available to the broader scientific community in order to meet the charitable objectives of the Grand Challenges Initiative. Flavell will collaborate with the Institute for Research in Biomedicine in Switzerland and with Regeneron Pharmaceuticals in Tarrytown, New York.

The team will engineer a mouse model in which critical components of the human immune syste m replace the similar regions of the mouse. A new technology developed at the Institute for Research in Biomedicine introduces cells from human umbilical cord blood into mice to establish a human immune system. "Using this technology and the genetic modification of the mouse, we will end up with a reasonably faithful replica of the human immune system," said Flavell.

The project is titled "A Mouse Model to Evaluate Live-Attenuated Vaccine Candidates."


'"/>

Source:Yale University


Related biology news :

1. Measurement Challenges In Detecting Cancer Biomarkers
2. Global analysis of membrane proteins
3. Global warming increases oyster sensitivity to pollution
4. Global study shows all tobacco bad for the heart
5. Global warming may warrant new approaches to ecosystem restoration
6. Global warming may have damaged coral reefs forever
7. Global malaria map key weapon in fight against malaria, scientists say
8. Global changes alter the timing of plant growth, scientists say
9. Global map shows new patterns of extinction risk
10. Global sunscreen has likely thinned, report NASA scientists
11. Global survey of lizards reveals greater abundance of animals on islands than on mainland ecosystems
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/19/2019)... ... November 19, 2019 , ... Hosted at the Las Vegas Convention Center, and ... is the largest gathering of MJBiz business professionals in the world. With over 1,300 ... sector, there is no show quite like it. Atlantic Ultraviolet will exhibit at Booth ...
(Date:11/12/2019)... ... November 12, 2019 , ... G5, the leader ... advertising performance up to 25% and reduces cost-per-click by as much as 15%. ... multi-touch attribution (MTA) to predict best advertising outcomes and automatically allocate daily ad ...
(Date:11/9/2019)... , ... November 08, 2019 ... ... Pathology to form the leading provider of specialized histology, pathology, biomarker development, ... StageBio was recently created by the mergers of Histo-Scientific Research Laboratories (HSRL), ...
Breaking Biology News(10 mins):
(Date:10/10/2019)... ... October 10, 2019 , ... ... largest network of clinical research centers in Europe. All Pratia research centers have ... Europe to become trained and certified as Virtual Trial Capable and prepared to ...
(Date:10/8/2019)... MELBOURNE, Fla. (PRWEB) , ... October 07, 2019 ... ... and development of low level laser therapy technology (“3LT®”), today announces that the ... to market its EVRL low level laser for the temporary relief of chronic ...
(Date:10/3/2019)... ... 01, 2019 , ... Today Cereset®, the only proven non-invasive ... of its randomized research trial for individuals with persisting symptoms following mild-Traumatic Brain ... a non-invasive technology which compares tones delivered to a subject’s brain guided by ...
(Date:10/3/2019)... , ... October 02, 2019 , ... ... life sciences leadership firm that is enabling clinical program outsourcing success by cultivating ... by award-winning pharma and biotech veteran executive Brenda Reese, phaseUP™ brings clients deep, ...
Breaking Biology Technology: